Literature DB >> 1308762

Effective dose from radiopharmaceuticals.

L Johansson1, S Mattsson, B Nosslin, S Leide-Svegborn.   

Abstract

The effective dose, as defined by the International Commission on Radiological Protection (ICRP 1991), provides a possibility of expressing the radiation risk to patients undergoing different radiodiagnostic procedures by means of a single figure. This has been obtained by introducing organ or tissue weighting factors reflecting the radiation sensitivity of the organs. Such weighting factors were first published by the ICRP in publication 26 (1977), and have now been revised in publication 60 (1991). The effective dose for almost all radiopharmaceuticals in clinical use has been recalculated using the new weighting factors from ICRP 60 (1991) and compared with results from former calculations. A slight decrease in the numerical value for the effective dose has been observed, on average 11%. However, this does not correspond to a decrease in the estimated risk from the irradiation, since this has been re-evaluated and found to be higher than earlier believed (NAS 1990; ICRP 1991).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1308762     DOI: 10.1007/bf00175858

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  1 in total

1.  Effective dose equivalent from radiopharmaceuticals.

Authors:  L Johansson; S Mattsson; B Nosslin
Journal:  Eur J Nucl Med       Date:  1984
  1 in total
  17 in total

1.  Automatic alignment of myocardial perfusion PET and 64-slice coronary CT angiography on hybrid PET/CT.

Authors:  Ryo Nakazato; Damini Dey; Erick Alexánderson; Aloha Meave; Moisés Jiménez; Edgar Romero; Rodrigo Jácome; Marco Peña; Daniel S Berman; Piotr J Slomka
Journal:  J Nucl Cardiol       Date:  2012-03-15       Impact factor: 5.952

2.  Washout and redistribution between immediate and two-hour myocardial images using technetium-99m sestamibi.

Authors:  W S Richter; M Cordes; D Calder; H Eichstaedt; R Felix
Journal:  Eur J Nucl Med       Date:  1995-01

3.  Effect of revised ICRP recommendations on krypton-81m dosimetry--or a discrepancy?

Authors:  M M Gupta; A Nagaratnam
Journal:  Eur J Nucl Med       Date:  1996-02

4.  Hypodense regions in unenhanced CT identify nonviable myocardium: validation versus 18F-FDG PET.

Authors:  Tobias A Fuchs; Jelena R Ghadri; Julia Stehli; Catherine Gebhard; Egle Kazakauskaite; Bernd Klaeser; Oliver Gaemperli; Michael Fiechter; Philipp A Kaufmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-28       Impact factor: 9.236

Review 5.  The impact of W. K. Röntgen's discovery on the use of internalizable sources of ionizing energy in diagnostic and therapeutic nuclear medicine.

Authors:  H Rösler
Journal:  Experientia       Date:  1995-07-14

6.  Effective dose from radiopharmaceuticals.

Authors:  S C Jain
Journal:  Eur J Nucl Med       Date:  1993-08

7.  Effective dose from radiopharmaceuticals.

Authors:  M A Macleod; P M Kemp
Journal:  Eur J Nucl Med       Date:  1993-05

Review 8.  Carcinogenic risk in diagnostic nuclear medicine: biological and epidemiological considerations.

Authors:  F Overbeek; E K Pauwels; J J Broerse
Journal:  Eur J Nucl Med       Date:  1994-09

9.  Pharmacokinetics and radiation dose of oxygen-15 labelled butanol in rCBF studies in humans.

Authors:  H Herzog; R J Seitz; L Tellmann; G Schlaug; A Kleinschmidt; B Nebeling; G Stöcklin; H W Müller-Gärtner
Journal:  Eur J Nucl Med       Date:  1994-02

10.  PET radiopharmaceuticals in Europe: current use and data relevant for the formulation of summaries of product characteristics (SPCs).

Authors:  G J Meyer; S L Waters; H H Coenen; A Luxen; B Maziere; B Langström
Journal:  Eur J Nucl Med       Date:  1995-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.